|
Safety of cabazitaxel (Cbz) in patients (pt) with metastatic transitional-cell carcinoma (mTCC) progressing to cisplatin-based chemotherapy: Results from the JEVTCC-SOGUG Study. |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Janssen (I); Sanofi |
Speakers' Bureau - Astellas Pharma; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
Research Funding - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
Speakers' Bureau - Sanofi |
Travel, Accommodations, Expenses - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
Aranzazu Gonzalez del Alba |
Consulting or Advisory Role - Astellas Pharma; Bayer; Sanofi |
Speakers' Bureau - Bayer; GlaxoSmithKline; Janssen-Cilag |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |